QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, September 13, 2006, 26(37):9385-9393; doi:10.1523/JNEUROSCI.1246-06.2006

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (56) Citing Articles via Google Scholar Google Scholar Articles by Cui, M. Articles by Faltynek, C. R. Search for Related Content PubMed PubMed Citation Articles by Cui, M. Articles by Faltynek, C. R.

 Previous Article  |  Next Article 

Behavioral/Systems/Cognitive
TRPV1 Receptors in the CNS Play a Key Role in Broad-Spectrum Analgesia of TRPV1 Antagonists

M. Cui, P. Honore, C. Zhong, D. Gauvin, J. Mikusa, G. Hernandez, P. Chandran, A. Gomtsyan, B. Brown, E. K. Bayburt, K. Marsh, B. Bianchi, H. McDonald, W. Niforatos, T. R. Neelands, R. B. Moreland, M. W. Decker, C.-H. Lee, J. P. Sullivan, and C. R. Faltynek

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064-6123

Correspondence should be addressed to Dr. Prisca Honore, Abbott Laboratories, Department R4N5, Building AP9A-LL, 100 Abbott Park Road, Abbott Park, IL 60064. Email: marie.honore{at}abbott.com

Vanilloid receptor type 1 (TRPV1) is a ligand-gated nonselective cation channel that is considered to be an important integrator of various pain stimuli such as endogenous lipids, capsaicin, heat, and low pH. In addition to expression in primary afferents, TRPV1 is also expressed in the CNS. To test the hypothesis that the CNS plays a differential role in the effect of TRPV1 antagonists in various types of pain, the analgesic effects of two TRPV1 antagonists with similar in vitro potency but different CNS penetration were compared in vivo. Oral administration of either A-784168 (1-[3-(trifluoromethyl)pyridin-2-yl]-N-[4-(trifluoromethylsulfonyl)phenyl]-1,2,3,6-tetrahydropyridine-4-carboxamide) (good CNS penetration) or A-795614 (N-1H-indazol-4-yl-N'-[(1R)-5-piperidin-1-yl-2,3-dihydro-1H-inden-1-yl]urea) (poor CNS penetration) blocked capsaicin-induced acute pain with the same potency. In complete Freund's adjuvant (CFA)-induced chronic inflammatory pain, oral administration of either compound blocked thermal hyperalgesia with similar potency. Furthermore, intraplantar or intrathecal administration of A-784168 blocked CFA-induced thermal hyperalgesia, suggesting that both peripheral and CNS TRPV1 receptors may play a role in inflammatory thermal hyperalgesia. The effects of the two TRPV1 antagonists were further assessed in models presumably mediated by central sensitization, including CFA- and capsaicin-induced mechanical allodynia and osteoarthritic pain. In these models, the potency of the two compounds was similar after intrathecal administration. However, when administered orally, A-784168, with good CNS penetration, was much more potent than A-795614. Together, these results demonstrate that TRPV1 receptors in the CNS play an important role in pain mediated by central sensitization. In addition, these results demonstrate that significant CNS penetration is necessary for a TRPV1 antagonist to produce broad-spectrum analgesia.

Key words: behavior; capsaicin; nociception; osteoarthritis; pharmacology; VR1

---

Received March 23, 2006; revised Aug. 3, 2006; accepted Aug. 4, 2006.

Correspondence should be addressed to Dr. Prisca Honore, Abbott Laboratories, Department R4N5, Building AP9A-LL, 100 Abbott Park Road, Abbott Park, IL 60064. Email: marie.honore{at}abbott.com

This article has been cited by other articles:

				A. M. Patwardhan, P. E. Scotland, A. N. Akopian, and K. M. Hargreaves From the Cover: Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia PNAS, November 3, 2009; 106(44): 18820 - 18824. [Abstract] [Full Text] [PDF]

				D. Spicarova and J. Palecek The Role of The TRPV1 Endogenous Agonist N-Oleoyldopamine in Modulation of Nociceptive Signaling at the Spinal Cord Level J Neurophysiol, July 1, 2009; 102(1): 234 - 243. [Abstract] [Full Text] [PDF]

				S. McGaraughty, K. L. Chu, B. S. Brown, C. Z. Zhu, C. Zhong, S. K. Joshi, P. Honore, C. R. Faltynek, and M. F. Jarvis Contributions of Central and Peripheral TRPV1 Receptors to Mechanically Evoked and Spontaneous Firing of Spinal Neurons in Inflamed Rats J Neurophysiol, December 1, 2008; 100(6): 3158 - 3166. [Abstract] [Full Text] [PDF]

				H.-Y. Zhou, S.-R. Chen, H. Chen, and H.-L. Pan Sustained Inhibition of Neurotransmitter Release from Nontransient Receptor Potential Vanilloid Type 1-Expressing Primary Afferents by {micro}-Opioid Receptor Activation-Enkephalin in the Spinal Cord J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 375 - 382. [Abstract] [Full Text] [PDF]

				C. S. Surowy, T. R. Neelands, B. R. Bianchi, S. McGaraughty, R. El Kouhen, P. Han, K. L. Chu, H. A. McDonald, M. Vos, W. Niforatos, et al. (R)-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal Activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-Evoked Firing of Spinal Dorsal Horn Neurons in Vivo J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 879 - 888. [Abstract] [Full Text] [PDF]

				Y. V. Medvedeva, M.-S. Kim, and Y. M. Usachev Mechanisms of Prolonged Presynaptic Ca2+ Signaling and Glutamate Release Induced by TRPV1 Activation in Rat Sensory Neurons J. Neurosci., May 14, 2008; 28(20): 5295 - 5311. [Abstract] [Full Text] [PDF]

				K. Schnizler, L. P. Shutov, M. J. Van Kanegan, M. A. Merrill, B. Nichols, G. S. McKnight, S. Strack, J. W. Hell, and Y. M. Usachev Protein Kinase A Anchoring via AKAP150 Is Essential for TRPV1 Modulation by Forskolin and Prostaglandin E2 in Mouse Sensory Neurons J. Neurosci., May 7, 2008; 28(19): 4904 - 4917. [Abstract] [Full Text] [PDF]

				K. Starowicz, S. Maione, L. Cristino, E. Palazzo, I. Marabese, F. Rossi, V. de Novellis, and V. Di Marzo Tonic Endovanilloid Facilitation of Glutamate Release in Brainstem Descending Antinociceptive Pathways J. Neurosci., December 12, 2007; 27(50): 13739 - 13749. [Abstract] [Full Text] [PDF]

				N. R. Gavva, A. W. Bannon, D. N. Hovland Jr., S. G. Lehto, L. Klionsky, S. Surapaneni, D. C. Immke, C. Henley, L. Arik, A. Bak, et al. Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 128 - 137. [Abstract] [Full Text] [PDF]

				B. R. Bianchi, R. El Kouhen, T. R. Neelands, C.-H. Lee, A. Gomtsyan, S. N. Raja, S. N. Vaidyanathan, B. Surber, H. A. McDonald, C. S. Surowy, et al. [3H]A-778317 [1-((R)-5-tert-Butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a Novel, Stereoselective, High-Affinity Antagonist Is a Useful Radioligand for the Human Transient Receptor Potential Vanilloid-1 (TRPV1) Receptor J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 285 - 293. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help